These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 12821497

  • 21. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy.
    Beutner KR.
    Antiviral Res; 1995 Dec; 28(4):281-90. PubMed ID: 8669888
    [Abstract] [Full Text] [Related]

  • 22. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.
    Steingrimsdottir H, Gruber A, Palm C, Grimfors G, Kalin M, Eksborg S.
    Antimicrob Agents Chemother; 2000 Jan; 44(1):207-9. PubMed ID: 10602752
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function.
    Smith JP, Weller S, Johnson B, Nicotera J, Luther JM, Haas DW.
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1146-51. PubMed ID: 20038622
    [Abstract] [Full Text] [Related]

  • 24. A new paediatric formulation of valaciclovir: development and bioequivalence assessment.
    Bastiaans DE, Bartels-Wilmer CM, Colbers AP, Heijens CA, Velthoven-Graafland K, Smeets OS, Vink N, Harbers VE, Warris A, Burger DM.
    Arch Dis Child; 2016 Oct; 101(10):971-2. PubMed ID: 27162003
    [No Abstract] [Full Text] [Related]

  • 25. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
    Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, Smiley ML.
    Clin Pharmacol Ther; 1993 Dec; 54(6):595-605. PubMed ID: 8275615
    [Abstract] [Full Text] [Related]

  • 26. Extrapolation of Valacyclovir Posology to Children Based on Pharmacokinetic Modeling.
    Kechagia IA, Kalantzi L, Dokoumetzidis A.
    Pediatr Infect Dis J; 2015 Dec; 34(12):1342-8. PubMed ID: 26379165
    [Abstract] [Full Text] [Related]

  • 27. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children.
    Nadal D, Leverger G, Sokal EM, Floret D, Perel Y, Leibundgut K, Weller S.
    J Infect Dis; 2002 Oct 15; 186 Suppl 1():S123-30. PubMed ID: 12353197
    [Abstract] [Full Text] [Related]

  • 28. Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.
    Sabo JP, Cong XJ, Kraft MF, Wallace L, Castles MA, Mauss S, MacGregor TR.
    Eur J Clin Pharmacol; 2011 Mar 15; 67(3):277-81. PubMed ID: 20963404
    [Abstract] [Full Text] [Related]

  • 29. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line.
    Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ.
    J Pharmacol Exp Ther; 1999 Apr 15; 289(1):448-54. PubMed ID: 10087037
    [Abstract] [Full Text] [Related]

  • 30. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
    Tyring SK, Douglas JM, Corey L, Spruance SL, Esmann J.
    Arch Dermatol; 1998 Feb 15; 134(2):185-91. PubMed ID: 9487210
    [Abstract] [Full Text] [Related]

  • 31. Drug inhibition of Gly-Sar uptake and hPepT1 localization using hPepT1-GFP fusion protein.
    Sun D, Landowski CP, Chu X, Wallsten R, Komorowski TE, Fleisher D, Amidon GL.
    AAPS PharmSci; 2001 Feb 15; 3(1):E2. PubMed ID: 11741253
    [Abstract] [Full Text] [Related]

  • 32. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
    Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J.
    Antimicrob Agents Chemother; 1995 Dec 15; 39(12):2759-64. PubMed ID: 8593015
    [Abstract] [Full Text] [Related]

  • 33. Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea.
    Anand BS, Mitra AK.
    Pharm Res; 2002 Aug 15; 19(8):1194-202. PubMed ID: 12240946
    [Abstract] [Full Text] [Related]

  • 34. Valacyclovir for the treatment of Bell's palsy.
    Hato N, Sawai N, Teraoka M, Wakisaka H, Takahashi H, Hinohira Y, Gyo K.
    Expert Opin Pharmacother; 2008 Oct 15; 9(14):2531-6. PubMed ID: 18778190
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Valacyclovir and acyclovir pharmacokinetics in immunocompromised children.
    Bomgaars L, Thompson P, Berg S, Serabe B, Aleksic A, Blaney S.
    Pediatr Blood Cancer; 2008 Oct 15; 51(4):504-8. PubMed ID: 18561175
    [Abstract] [Full Text] [Related]

  • 38. In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1.
    Pak YA, Long AJ, Annes WF, Witcher JW, Knadler MP, Ayan-Oshodi MA, Mitchell MI, Leese P, Hillgren KM.
    Drug Metab Dispos; 2017 Feb 15; 45(2):137-144. PubMed ID: 27895114
    [Abstract] [Full Text] [Related]

  • 39. Valacyclovir as Initial Treatment for Acute Retinal Necrosis: A Pharmacokinetic Modeling and Simulation Study.
    Liu T, Jain A, Fung M, Vinnard C, Ivaturi V.
    Curr Eye Res; 2017 Jul 15; 42(7):1035-1038. PubMed ID: 28358222
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
    Wang LH, Schultz M, Weller S, Smiley ML, Blum MR.
    Antimicrob Agents Chemother; 1996 Jan 15; 40(1):80-5. PubMed ID: 8787884
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.